The Diagnosis and Treatment of Osteosarcoma and Ewing's Sarcoma in Children and Adolescents
Overview
Affiliations
Background: Osteosarcoma and Ewing's sarcoma in children and adolescents require age-specific interdisciplinary diagnosis and treatment to achieve optimal therapeutic outcomes.
Methods: The diagnosis and treatment of malignant bone tumors in childhood and adolescence are presented in the light of publications retrieved by a selective search, pertinent guidelines, and the authors' extensive experience in an interdisciplinary cancer center.
Results: Bone sarcomas make up approximately 5% of all malignancies in children and adolescents; the most common types are Ewing's sarcoma and osteosarcoma. Patients are often not referred to a specialized center until long after the onset of symptoms, as they and their physicians rarely consider the possibility of a bone tumor, and the symptoms are often trivialized. Bone pain of unknown origin, swelling, and functional limitations should be investigated with conventional x-rays. Lesions of unclear origin should be biopsied after a meticulous clinical and radiologic evaluation. Multimodal treatment consists of neo - adjuvant chemotherapy, limb-preserving resection if possible, and radiotherapy where indicated. In multicenter studies, patients with osteosarcoma achieve event-free survival in 64% of cases if their disease is localized, and 28% if it is metastatic; the corresponding figures for patients with Ewing's sarcoma are 80% and 27%, respectively.
Conclusion: With implementation of the current treatment recommendations, most children and adolescents with malignant bone tumors can be treated successfully with curative intent. These patients should be referred to a sarcoma center for diagnosis and treatment.
A 10-year bibliometric analysis in the field of osteosarcoma treatment from 2014 to 2023.
Shen Y, Shao X, Chen J, Tang X Discov Oncol. 2025; 16(1):255.
PMID: 40019638 PMC: 11871176. DOI: 10.1007/s12672-025-02007-2.
Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics.
Li B, Zhang C, Xu X, Shen Q, Luo S, Hu J Front Immunol. 2025; 16:1539396.
PMID: 39991153 PMC: 11842356. DOI: 10.3389/fimmu.2025.1539396.
Degang T, Wei X, Jianying S, Aining L, Chenyu J, Haitang L Medicine (Baltimore). 2025; 104(7):e41489.
PMID: 39960964 PMC: 11835080. DOI: 10.1097/MD.0000000000041489.
Wang P, Lu H, Zhang C, Wang R, Chen X, Qiao L Sci Rep. 2025; 15(1):5484.
PMID: 39953179 PMC: 11829052. DOI: 10.1038/s41598-025-89766-8.
Clinical and Pathological Profile of Children and Adolescents with Osteosarcoma.
Ivan A, Cojocaru E, Sirbu P, Al Namat D, Tirnovanu S, Butnariu L Diagnostics (Basel). 2025; 15(3).
PMID: 39941196 PMC: 11817002. DOI: 10.3390/diagnostics15030266.